New developments in anti-HIV chemotherapy

Area of Science:

• Virology
• Pharmacology
• Medicinal Chemistry

Background:

• Current HIV therapies predominantly utilize three main drug classes: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
• These established drug classes target key enzymes and processes within the HIV replication cycle.

Purpose of the Study:

• To provide an overview of the current landscape of anti-HIV therapeutics.
• To highlight emerging drug classes and potential new targets in the HIV replication cycle.
• To emphasize the complexity of HIV drug action within intact cells.

Main Methods:

• Review of existing literature on HIV therapeutics.
• Classification of anti-HIV compounds based on their mechanism of action.
• Identification of additional targets within the HIV replicative cycle for therapeutic intervention.

Main Results:

• Established anti-HIV drugs fall into NRTI, NNRTI, and PI categories, with specific examples provided for each.
• Newer agents within these classes exhibit improved metabolic profiles or activity against resistant strains.
• Potential therapeutic targets extend beyond reverse transcriptase and protease to include viral entry, fusion, assembly, and integration.

Conclusions:

• The development of anti-HIV agents is multifaceted, targeting various stages of the viral life cycle.
• Ongoing research focuses on novel drug classes and improved versions of existing ones to combat resistant strains.
• Caution is advised when interpreting in vitro enzymatic assay results in the context of in vivo cellular activity.